• NF 449: From P2X1 Potency to Translation

  2026-08-13

  NF 449 is a highly selective purinergic receptor antagonist that helps translational researchers separate P2X1-driven platelet signaling from broader purinergic effects. This thought-leadership perspective connects receptor pharmacology with assay design, antithrombotic agent research, and more disciplined decisions about translation.

• TH287 MTH1 Inhibitor for Radiosensitization

  2026-08-13

  TH287 converts oxidized nucleotide stress into a controllable DNA-damage vulnerability, making it useful for mechanistic cancer assays and radiotherapy-combination studies. Its most distinctive application is schedule-sensitive radiosensitization, with early ionizing radiation after drug exposure showing strong activity in castration-resistant prostate cancer models.

• AMG 9810: A TRPV1 Stress-Response Probe

  2026-08-12

  AMG 9810 is a selective TRPV1 antagonist for separating sensory ion-channel signaling from metabolic stress responses. This article connects calcium and CGRP assays with the AMPK–SQSTM1–NRF2 framework while defining the limits of that cross-domain interpretation.

• WST-8 Glucose Uptake Assay Kit for Hepatic Models

  2026-08-12

  Connect hepatic insulin-resistance phenotypes to a practical, non-radioactive glucose uptake readout in hepatocytes and other cell models. This workflow shows how the WST-8 Glucose Uptake Assay Kit can complement autophagy, lipid-accumulation, and genetic-interaction experiments inspired by the Galectin-1–FIP200 axis.

• 5-hme-dCTP for DNA Hydroxymethylation Assays

  2026-08-11

  5-hme-dCTP enables controlled production of 5hmC-containing DNA for polymerase screening, assay calibration, and epigenetic method development. Its strongest use is as a defined modified-nucleotide substrate that complements, rather than replaces, genome-wide hydroxymethylation mapping in plant stress studies.

• 5-hme-dCTP for 5hmC Assay Workflows

  2026-08-11

  5-hme-dCTP provides a practical substrate for testing DNA polymerase compatibility, building hydroxymethylated DNA controls, and strengthening epigenetic assay validation. Its greatest value is upstream of interpretation: it helps researchers separate chemistry and workflow limitations from genuine 5hmC biology in plant stress and gene regulation studies.

• Palonosetron: Selectivity, PK, and CINV

  2026-08-10

  The reference study presents palonosetron hydrochloride as a highly selective 5-HT3 receptor antagonist with unusually strong receptor affinity, sustained antiemetic activity, and an approximately 40-hour elimination half-life. Its randomized clinical evidence showed noninferior control of acute chemotherapy-related nausea and vomiting and superior control of delayed symptoms versus granisetron, supporting a longer-acting approach to supportive cancer care.

• Digoxin B7684 for Reliable Cell Assays

  2026-08-09

  Learn how Digoxin (SKU B7684) can improve the interpretation and reproducibility of cell viability, proliferation, and chikungunya virus assays through mechanism-aware controls, solvent management, and cell-type-specific dosing. The article provides practical guidance for selecting and handling a Na+/K+ ATPase pump inhibitor in biomedical workflows.

• PFHxS Disrupts Zebrafish Lipid Homeostasis via PPARα

  2026-08-08

  The 2024 Environmental Science & Technology study shows that environmentally detected PFHxS concentrations disrupt lipid homeostasis in zebrafish larvae and implicates PPARα activation as a molecular initiating event. By integrating lipidomics, transcriptomics, molecular simulation, and antagonist coexposure, the work connects PFHxS exposure with changes in multiple lipid classes and downstream metabolic pathways.

• Olive Biophenols and Alzheimer’s Pathology: Study Insights

  2026-08-07

  The reference study connects direct inhibition of Aβ42 aggregation with protection of SH-SY5Y neuroblastoma cells and reduced plaque deposition in APPswe/PS1dE9 mice. Its principal contribution is a staged evaluation of olive biophenols, identifying oleuropein, verbascoside, and rutin as leading anti-amyloidogenic candidates while also highlighting unresolved questions about mechanism, bioavailability, and blood–brain barrier penetration.

• N-MYC/eIF4G1 Axis Drives Survival in inv(16) AML: New Insigh

  2026-08-07

  This study reveals that N-MYC is overexpressed in inv(16) acute myeloid leukemia (AML) and directly regulates cell survival via eIF4G1, a previously unrecognized oncogenic effector in this context. These findings illuminate a novel transcriptional program in leukemogenesis and offer a strong rationale for targeting the N-MYC/eIF4G1 axis in future therapeutic strategies.

• Alosetron: 5-HT3 Receptor Antagonist for Intestinal Polarity

  2026-08-06

  Alosetron from APExBIO empowers precision dissection of 5-HT3 receptor signaling in gut epithelial polarity and stem cell fate models. This guide details optimized workflows, troubleshooting strategies, and novel assay designs inspired by recent CDC42-YAP-mTOR pathway discoveries.

• Trichostatin A (TSA): Protocols and Innovations in Epigeneti

  2026-08-06

  Trichostatin A (TSA) is a gold-standard HDAC inhibitor enabling advanced epigenetic modulation in cancer and regenerative research. This guide details applied workflows, troubleshooting solutions, and new experimental frontiers inspired by nerve-mediated HDAC regulation in regeneration. Discover how APExBIO's TSA empowers reproducible, high-impact results.

• Dabigatran Etexilate: Transforming Thrombin Inhibition in Re

  2026-08-05

  This thought-leadership article explores how dabigatran etexilate, a potent oral direct thrombin inhibitor, is reshaping translational anticoagulant research. We combine mechanistic insight with pragmatic guidance, referencing clinical evidence and APExBIO's high-purity offering to guide protocol optimization and future directions in atrial fibrillation and stroke studies.

• Berberine Prevents AF via SIRT6-AMPK-Mediated NLRP3 Inhibiti

  2026-08-05

  This study reveals that berberine suppresses atrial fibrosis and atrial fibrillation susceptibility by activating the SIRT6-AMPK pathway and inhibiting NLRP3 inflammasome signaling. These findings clarify a mechanistic link between metabolic and inflammatory pathways in cardiac remodeling, offering a focused target for future anti-arrhythmic research.

550 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page